Vasculitis trials
Trials open to recruitment

APRIL
Rheumatoid arthritis is a multi-system, autoimmune disease characterised by progressive inflammation and destruction of synovial joints and extra-articular structures. In recent decades, the natural history of rheumatoid arthritis (RA) has…

BIOVAS
Glucocorticoids remain the standard therapy for remission induction in non-ANCA associated vasculitis (NAAV) and are used with or without immunosuppressive agents depending on the syndrome and severity. Glucocorticoids at high doses control…

OBIVAS
ObiVas is a randomised, phase II, double blind, controlled trial designed to evaluate the mechanistic effect of obinutuzumab versus rituximab in active AAV. Participants will be randomised to one of two treatment groups in a 1:1 ratio and receive…